Greenway Medical Technologies, Inc. (GWAY), Five Star Quality Care, Inc. (FVE), Astex Pharmaceuticals, Inc. (ASTX): Three Horrendous Health-Care Stocks This Week

The biotech reported first-quarter earnings of $488,000, or $0.01 per share, down from $4.2 million, or $0.05 per share, in the same period from last year. Revenue for the quarter totaled $22,1 million, only slightly higher than the $22 million reported for first quarter 2012.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) hopes to eventually transition from dependence on bone marrow disease drug Dacogen for its viability. The company has several drugs in mid-stage clinical studies, including experimental candidate SGI-110, which targets treatment of myelodysplastic syndromes and acute myeloid leukemia.

Blue skies
Does Willie Nelson need to write a depressing country song for all three of these stocks? Maybe not.

I think Greenway Medical Technologies, Inc. (NYSE:GWAY) could see blue skies ahead. The company’s woes seem to be largely transitory in nature. The market for health technology should remain strong, and I think Greenway’s shift to the software-as-a-service revenue model will be good over the long run.

However, I think there are better plays in this health technology sector. Like most investors, finding the best stocks out there is always on my mind.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.